New Treatment Guidelines for Ankylosing Spondylitis
The American College of Rheumatology has published new guidelines for the treatment of ankylosing spondylitis, emphasizing the strong evidence for treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and tumor necrosis factor (TNF) blockers.
A committee of rheumatology experts evaluated the evidence for these and other treatments for both active and stable ankylosing spondylitis (AS); for ankylosing spondylitis plus comorbidities; and, for non-radiographic spondyloarthritis. They considered studies that examined health status, functional status, morbidities and adverse events, focusing on the clinical questions that physicians and patients wrestle with daily.
The resulting recommendations are qualified as “strongly in favor,” “conditionally in favor,” “conditionally against” and “strongly against.” Strong recommendations should be accepted by most patients offered the treatment, while conditional recommendations require education and shared decision-making, the researchers wrote.